%0
Generic
%T
Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.
%A Nauseef, Jones T.
%A Singh, Sharon
%A Tan, Angela
%A Patel, Amie
%A Robinson, Brian D.
%A Khani, Francesca
%A Drake, Charles G.
%A Lim, Emerson A.
%A Stein, Mark N.
%A Heath, Elisabeth I.
%A Beltran, Himisha
%A Molina, Ana M.
%A Faltas, Bishoy Morris
%A Ballman, Karla V.
%A Sternberg, Cora N.
%A Tagawa, Scott T.
%A Nanus, David M.
%I American Society of Clinical Oncology (ASCO)
%@ 0732-183X
%@ 1527-7755
%K Cancer Research
%K Oncology
%D 2021
%C American Society of Clinical Oncology (ASCO)
%U http://slubdd.de/katalog?TN_libero_mab2